Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217064 | 1.00 | MAPT (0.48) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL21210733 | 1.00 | MAPT (0.48) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL29713365 | 0.98 | MAPT (0.45) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL12597236 | 0.91 | MAPT (0.42) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL15042268 | 0.89 | MAPT (0.52) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL1063939 | 0.84 | MAPT (0.52) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL8108080 | 0.82 | — | — | |
| SCHEMBL24259167 | 0.82 | MAPT (0.47) | MAPTTSHRMEN1LMNAKMT2A | |
| SCHEMBL19188713 | 0.79 | MAPT (0.44) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL9471464 | 0.78 | TSHR (0.53) | MAPTTSHRMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9048436-B2 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140299822-A1 | Oxadiazole Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Oxadiazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20130200344-A1 | Oxadiazole Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Oxadiazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8389735-B2 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20070149784-A1 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149784-A1 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | OXA1L, ADRA1D, CRY1 | MAPT 3287/4885TSHR 1930/4885MEN1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.